In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo

Clarissa Hernandez Stephens, Kara S. Orr, Anthony J. Acton, Sarah A. Tersey, Raghu Mirmira, Robert Considine, Sherry L. Voytik-Harbin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Wide-spread use of pancreatic islet transplantation for treatment of type 1 diabetes (T1D) is currently limited by requirements for long-term immunosuppression, limited donor supply, and poor long-term engraftment and function. Upon isolation from their native microenvironment, islets undergo rapid apoptosis, which is further exacerbated by poor oxygen and nutrient supply following infusion into the portal vein. Identifying alternative strategies to restore critical microenvi-ronmental cues, while maximizing islet health and function, is needed to advance this cellular therapy. We hypothesized that biophysical properties provided through type I oligomeric collagen macroencapsulation are important considerations when designing strategies to improve islet survival, phenotype, and function. Mouse islets were encapsulated at various Oligomer concentrations (0.5–3.0 mg/ml) or suspended in media and cultured for 14 days, after which viability, protein expression, and function were assessed. Oligomer-encapsu-lated islets showed a density-dependent improvement in in vitro viability, cytoarchitecture, and insulin secretion, with 3 mg/ml yielding values comparable to freshly isolated islets. For transplantation into streptozotocin-induced diabetic mice, 500 islets were mixed in Oligomer and injected subcutaneously, where rapid in situ macroencapsulation occurred, or injected with saline. Mice treated with Oli-gomer-encapsulated islets exhibited rapid (within 24 h) diabetes reversal and maintenance of normoglycemia for 14 (immunocompro-mised), 90 (syngeneic), and 40 days (allogeneic). Histological analysis showed Oligomer-islet engraftment with maintenance of islet cytoarchitecture, revascularization, and no foreign body response. Oligomer-islet macroencapsulation may provide a useful strategy for prolonging the health and function of cultured islets and has potential as a subcutaneous injectable islet transplantation strategy for treatment of T1D.

Original languageEnglish (US)
Pages (from-to)E650-E661
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume315
Issue number4
DOIs
StatePublished - Oct 6 2018

Fingerprint

Collagen Type I
Islets of Langerhans Transplantation
Type 1 Diabetes Mellitus
Maintenance
Health
Streptozocin
Portal Vein
Foreign Bodies
Immunosuppression
Cues
Therapeutics
Transplantation
Insulin
Apoptosis
Oxygen
Phenotype
Food
Injections
In Vitro Techniques
Proteins

Keywords

  • Islet encapsulation
  • Subcutaneous
  • Type 1 diabetes
  • Type I collagen oligomers

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Cite this

In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo. / Stephens, Clarissa Hernandez; Orr, Kara S.; Acton, Anthony J.; Tersey, Sarah A.; Mirmira, Raghu; Considine, Robert; Voytik-Harbin, Sherry L.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 315, No. 4, 06.10.2018, p. E650-E661.

Research output: Contribution to journalArticle

Stephens, Clarissa Hernandez ; Orr, Kara S. ; Acton, Anthony J. ; Tersey, Sarah A. ; Mirmira, Raghu ; Considine, Robert ; Voytik-Harbin, Sherry L. / In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo. In: American Journal of Physiology - Endocrinology and Metabolism. 2018 ; Vol. 315, No. 4. pp. E650-E661.
@article{bf0db11fea6f4d56a137c596b421eaa4,
title = "In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo",
abstract = "Wide-spread use of pancreatic islet transplantation for treatment of type 1 diabetes (T1D) is currently limited by requirements for long-term immunosuppression, limited donor supply, and poor long-term engraftment and function. Upon isolation from their native microenvironment, islets undergo rapid apoptosis, which is further exacerbated by poor oxygen and nutrient supply following infusion into the portal vein. Identifying alternative strategies to restore critical microenvi-ronmental cues, while maximizing islet health and function, is needed to advance this cellular therapy. We hypothesized that biophysical properties provided through type I oligomeric collagen macroencapsulation are important considerations when designing strategies to improve islet survival, phenotype, and function. Mouse islets were encapsulated at various Oligomer concentrations (0.5–3.0 mg/ml) or suspended in media and cultured for 14 days, after which viability, protein expression, and function were assessed. Oligomer-encapsu-lated islets showed a density-dependent improvement in in vitro viability, cytoarchitecture, and insulin secretion, with 3 mg/ml yielding values comparable to freshly isolated islets. For transplantation into streptozotocin-induced diabetic mice, 500 islets were mixed in Oligomer and injected subcutaneously, where rapid in situ macroencapsulation occurred, or injected with saline. Mice treated with Oli-gomer-encapsulated islets exhibited rapid (within 24 h) diabetes reversal and maintenance of normoglycemia for 14 (immunocompro-mised), 90 (syngeneic), and 40 days (allogeneic). Histological analysis showed Oligomer-islet engraftment with maintenance of islet cytoarchitecture, revascularization, and no foreign body response. Oligomer-islet macroencapsulation may provide a useful strategy for prolonging the health and function of cultured islets and has potential as a subcutaneous injectable islet transplantation strategy for treatment of T1D.",
keywords = "Islet encapsulation, Subcutaneous, Type 1 diabetes, Type I collagen oligomers",
author = "Stephens, {Clarissa Hernandez} and Orr, {Kara S.} and Acton, {Anthony J.} and Tersey, {Sarah A.} and Raghu Mirmira and Robert Considine and Voytik-Harbin, {Sherry L.}",
year = "2018",
month = "10",
day = "6",
doi = "10.1152/ajpendo.00073.2018",
language = "English (US)",
volume = "315",
pages = "E650--E661",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo

AU - Stephens, Clarissa Hernandez

AU - Orr, Kara S.

AU - Acton, Anthony J.

AU - Tersey, Sarah A.

AU - Mirmira, Raghu

AU - Considine, Robert

AU - Voytik-Harbin, Sherry L.

PY - 2018/10/6

Y1 - 2018/10/6

N2 - Wide-spread use of pancreatic islet transplantation for treatment of type 1 diabetes (T1D) is currently limited by requirements for long-term immunosuppression, limited donor supply, and poor long-term engraftment and function. Upon isolation from their native microenvironment, islets undergo rapid apoptosis, which is further exacerbated by poor oxygen and nutrient supply following infusion into the portal vein. Identifying alternative strategies to restore critical microenvi-ronmental cues, while maximizing islet health and function, is needed to advance this cellular therapy. We hypothesized that biophysical properties provided through type I oligomeric collagen macroencapsulation are important considerations when designing strategies to improve islet survival, phenotype, and function. Mouse islets were encapsulated at various Oligomer concentrations (0.5–3.0 mg/ml) or suspended in media and cultured for 14 days, after which viability, protein expression, and function were assessed. Oligomer-encapsu-lated islets showed a density-dependent improvement in in vitro viability, cytoarchitecture, and insulin secretion, with 3 mg/ml yielding values comparable to freshly isolated islets. For transplantation into streptozotocin-induced diabetic mice, 500 islets were mixed in Oligomer and injected subcutaneously, where rapid in situ macroencapsulation occurred, or injected with saline. Mice treated with Oli-gomer-encapsulated islets exhibited rapid (within 24 h) diabetes reversal and maintenance of normoglycemia for 14 (immunocompro-mised), 90 (syngeneic), and 40 days (allogeneic). Histological analysis showed Oligomer-islet engraftment with maintenance of islet cytoarchitecture, revascularization, and no foreign body response. Oligomer-islet macroencapsulation may provide a useful strategy for prolonging the health and function of cultured islets and has potential as a subcutaneous injectable islet transplantation strategy for treatment of T1D.

AB - Wide-spread use of pancreatic islet transplantation for treatment of type 1 diabetes (T1D) is currently limited by requirements for long-term immunosuppression, limited donor supply, and poor long-term engraftment and function. Upon isolation from their native microenvironment, islets undergo rapid apoptosis, which is further exacerbated by poor oxygen and nutrient supply following infusion into the portal vein. Identifying alternative strategies to restore critical microenvi-ronmental cues, while maximizing islet health and function, is needed to advance this cellular therapy. We hypothesized that biophysical properties provided through type I oligomeric collagen macroencapsulation are important considerations when designing strategies to improve islet survival, phenotype, and function. Mouse islets were encapsulated at various Oligomer concentrations (0.5–3.0 mg/ml) or suspended in media and cultured for 14 days, after which viability, protein expression, and function were assessed. Oligomer-encapsu-lated islets showed a density-dependent improvement in in vitro viability, cytoarchitecture, and insulin secretion, with 3 mg/ml yielding values comparable to freshly isolated islets. For transplantation into streptozotocin-induced diabetic mice, 500 islets were mixed in Oligomer and injected subcutaneously, where rapid in situ macroencapsulation occurred, or injected with saline. Mice treated with Oli-gomer-encapsulated islets exhibited rapid (within 24 h) diabetes reversal and maintenance of normoglycemia for 14 (immunocompro-mised), 90 (syngeneic), and 40 days (allogeneic). Histological analysis showed Oligomer-islet engraftment with maintenance of islet cytoarchitecture, revascularization, and no foreign body response. Oligomer-islet macroencapsulation may provide a useful strategy for prolonging the health and function of cultured islets and has potential as a subcutaneous injectable islet transplantation strategy for treatment of T1D.

KW - Islet encapsulation

KW - Subcutaneous

KW - Type 1 diabetes

KW - Type I collagen oligomers

UR - http://www.scopus.com/inward/record.url?scp=85054434560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054434560&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00073.2018

DO - 10.1152/ajpendo.00073.2018

M3 - Article

C2 - 29894201

AN - SCOPUS:85054434560

VL - 315

SP - E650-E661

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 4

ER -